###### Strengths and limitations of this study

-   The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort is an ongoing Danish cohort and biobank of newly diagnosed patients with type 2 diabetes (T2D) continuously enrolled on a nationwide level since 2010.

-   By 2016, 7011 patients have been recruited from general practitioners (53%) and hospital specialist outpatient clinics (47%).

-   The cohort includes baseline interview data, physical examination data, biological samples (DNA, blood and urine) as well as baseline and follow-up data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, incident cancers, mortality and causes of death.

-   The cohort may represent patients with more advanced T2D than average, and 85% already had initiated glucose-lowering treatment at enrolment that hampers studies of drug-naive patients with T2D.

-   In the future, the DD2 cohort will serve as a strong national and international resource for recruiting patients to nested clinical trials, large-scale genome studies and long-term follow-up studies of T2D complications through linkage with the large network of existing population-based registries in Denmark.

Introduction {#s1}
============

Type 2 diabetes (T2D) is associated with a wide range of devastating complications, classically including cardiovascular disease, end-stage renal disease, blindness, diabetic foot ulcers and amputations. T2D also increases risk of infections, some cancers and neuropsychiatric disease.[@R1] These complications inflict a burden on the healthcare system as well as on the individual patients with diabetes. Since it is hard to prevent T2D, there is a compelling need for cost-effective research to target and improve diabetes treatment in order to prevent complications. Fortunately, over the last decades, the number of available glucose-lowering treatment options has increased,[@R2] facilitating individually tailored treatment. In this context determining how genotype and phenotype may influence the optimal choice of treatment is essential.[@R3]

Denmark has a tax-supported healthcare system that includes free access to care at general practitioners (GPs) and hospitals as well as partial reimbursement for most prescribed drugs, including diabetes drugs.[@R4] GPs---the gatekeepers of the Danish National Health Service---are responsible for nearly all referrals to hospitals and specialists. Patient contacts with health and social services are extensively documented at the individual level in national databases using the unique civil personal registration number (CPR number) that has been assigned since 1968 to all Danish residents at birth or on immigration.[@R4]

In this setting, the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project was established in 2010. The Project's overall goal is to provide an international resource for T2D research. It encompasses establishment of the nationwide and data-rich DD2 cohort and a linked biobank of DNA, blood and urine. The study rationale has been to provide a platform for improved genotypic and clinical characterisation of T2D, for developing more individualised treatment and for testing new antidiabetic drugs in nested intervention studies. Moreover, to establish a unique T2D patient cohort by linkage with the large network of existing population-based registries in Denmark, through which patients can be followed longitudinally for a variety of clinical and socioeconomic outcomes for decades, allowing improved understanding of the predictors of long-term diabetes prognosis.

The aim of this cohort profile paper is to provide a description of the DD2 cohort as an international T2D research resource, including an overview of the collected data and a description of the baseline characteristics.

Cohort description {#s2}
==================

Study participants and recruitment {#s2a}
----------------------------------

Since 1 January 2009, all patients with newly or recently diagnosed T2D in Denmark have been eligible to participate in the DD2 cohort. The first patient was enrolled in November 2010, and the cohort now consists of 7011 patients. The DD2 project is ongoing, with continuous enrolment.

The process of enrolling in the DD2 cohort has been described in detail elsewhere[@R5]: (1) clinical providers (usually either the patient's GP or a hospital physician/nurse) identify patients newly diagnosed with T2D in routine clinical practice. (2) Those patients are informed by the clinical provider about the existence of the DD2 project. (3) Patients interested in participating receive detailed oral and written information and are asked to sign a written informed consent document for enrolment. (4) Patient clinical information is then collected: GPs or hospital physicians/nurses complete an online questionnaire, including items requiring a physical examination. (5) Urine and fasting blood samples are collected for storage in a biobank.[@R6]

Approximately 80% of patients with T2D in Denmark receive care at GPs' offices and the remainder at hospital specialist outpatient clinics. Enrolment into the DD2 cohort takes place in both settings ([figure 1](#F1){ref-type="fig"}). From 2010 to 2012, most patients were enrolled at hospital outpatient clinics rather than at GP offices (1559 vs 739 patients). From 2013 on, the number of patients recruited by GPs increased rapidly,[@R7] reaching 3688 in February 2016. As of that month, the corresponding number of patients recruited by outpatient specialist clinics was 3323 ([table 1](#T1){ref-type="table"}).

![Enrolment sites throughout Denmark. Every circle represents an enrolment site, either at a general practitioner's office or at an outpatient clinic. The administrative headquarter of the DD2 is in Odense (red dot). DD2, Danish Centre for Strategic Research in Type 2 Diabetes.](bmjopen-2017-017273f01){#F1}

###### 

Geographical distribution of DD2 participants by recruitment setting and year of enrolment

  Region             Hospital outpatient clinics, N   General practitioners' offices, N                                                                                   
  ------------------ -------------------------------- ----------------------------------- ----- ----- ----- ----- -------- ---------- ----- ----- ------ ----- ----- ---- ----------
  Capital            0                                23                                  246   197   199   85    5        755        7     144   259    134   39    5    588
  Central Denmark    18                               211                                 356   299   222   195   7        1308       0     38    192    84    72    5    391
  North Denmark      0                                2                                   52    16    73    19    5        167        0     31    276    161   30    0    498
  Zealand            0                                0                                   0     6     20    4     0        30         3     1     432    239   71    11   757
  Southern Denmark   0                                334                                 303   168   160   93    5        1063       184   324   237    147   471   50   1413
  Unspecified        --                               --                                  --    --    --    --    **--**   **--**     --    2     29     7     1     2    41
  Total Denmark      18                               570                                 957   686   674   396   22       **3323**   194   540   1425   772   684   73   **3688**

DD2, Danish Centre for Strategic Research in Type 2 Diabetes.

During the entire DD2 enrolment period, all diagnosing of T2D in routine clinical practice has been made according to WHO criteria, before 2012 primarily based on OGTT and after 2012 primarily based on glycosylated haemoglobin A (HbA1c) \>48 mmol/mol (6.5%). No further diagnostic criteria for enrolment have been applied in the DD2 project. The DD2 project explicitly aims to comprehensively study T2D as diagnosed in everyday clinical care, as one of the project aims is to document pitfalls in initial T2D diagnosing, including investigation of subtypes and subphenotypes in the cohort, occurrence of secondary diabetes, autoimmune diabetes and so on.

While the DD2 cohort from the beginning aimed to focus on newly diagnosed T2D patients, in clinical practice, the referral to DD2 may not happen at first diabetes notice when other clinical activity may be more pertinent. Individuals who have had prevalent T2D for some time after 2009 are also accepted for participation. While we do not have complete data on exact date of diabetes diagnosis for all individuals, average time from first recorded glucose-lowering drug initiation to enrolment date in the DD2 cohort is 1--1.5 years.

The exact proportion of all patients with incident T2D in Denmark that is enrolled into the DD2 cohort is unknown. With an average enrolment in the order of 1000--1200 DD2 patients per year, the project enrols an estimated 5% of newly diagnosed patients with T2D nationwide.

The number of enrolled patients and recruitment sites vary across the five Danish healthcare regions. Currently, the largest proportion (35%) of the cohort patients has been recruited from the region of Southern Denmark, which comprises 21% of Denmark's population, followed by the Central Denmark Region (with 24% of cohort patients) and the Capital Region (with 19% of cohort patients), comprising 22% and 31% of Denmark's population, respectively.

Loss of patients from the DD2 cohort can occur due to emigration and death. These events are identified by linkage to the Danish Civil Registration System (CRS), which has recorded vital status for the entire Danish population since 1968, with daily electronic updates.[@R4] Enrolled patients have the right to withdraw from the DD2 cohort, but only four individuals have done so thus far.

Data collection {#s2b}
---------------

Baseline data recorded in the DD2 database include each patient's CPR number, date of enrolment and DD2 variables collected directly at the enrolment visit (interview data, clinical examination data and biobank data). Furthermore, linkage with a wide range of Danish health and administrative registries, including the Danish Diabetes Database for Adults (DDDA), one of several Danish nationwide public clinical quality improvement registries,[@R7] ensures important additional baseline data ([figure 2](#F2){ref-type="fig"}).

![Flow chart of data collection in the DD2 cohort study. DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DDDA, Danish Diabetes Database for Adults; HbA1c, glycosylated haemoglobin A; SF-12, 12-Item Short Form Health Survey.](bmjopen-2017-017273f02){#F2}

The cohort is followed prospectively through linkage with the DDDA and other Danish administrative and health registries. Moreover, directly collected data are used to follow DD2 patients for outcomes not routinely available in medical registries as described below.

### Directly collected DD2 baseline variables {#s2b1}

These include waist--hip ratio, recalled body weight at age 20 years, maximum lifetime body weight, alcohol consumption, family history of diabetes, resting heart rate, physical activity level and (added in 2015) self-reported date of first T2D diagnosis. The self-reported physical activity level is currently being validated by placing accelerometers (AX3, Axivity, Newcastle, UK) directly on the skin of the thigh and back of persons in a subcohort of DD2 participants (n=1000), and all physical activity is recorded over a 10-day period. Moreover, a smartphone application ([www.interwalk.dk](www.interwalk.dk)) holding an interval-based training program has been developed. DD2 participants are encouraged to download and use this application, which guides and monitors their physical exercise. The logged exercise data are then transferred to the DD2 cohort and allow future investigations of for example, the impact of exercise on risk of T2D complications. Urine and blood samples (whole blood, serum, plasma and purified DNA) are stored in a biobank[@R6] and can be used for myriad purposes. To date, plasma samples have been analysed for a number of baseline variables, including fasting blood glucose, C-peptide (used in homeostatic model assessment of insulin resistance), glutamic acid decarboxylase antibodies, alanine-aminotransferases (ALAT), amylase and C reactive protein (CRP). Several currently initiated and planned studies will provide a larger range of analysed biobank variables. For instance, DNA has been purified from 6000 patients and 'maturity-onset diabetes of the young' (MODY) genes are now being sequenced in order to identify individuals carrying likely pathogenic variants. As well, studies of the prevalence of 'latent autoimmune diabetes in adults' in cohort members and the impact of the inflammatory system on diabetic complications have been initiated and will lead to analyses of additional biomarkers, including mannan-binding lectin.

### Variables provided by the DDDA {#s2b2}

The DDDA, established in 2005, provides a key source of supplemental individual-level data.[@R7] Quality of care data (variables outlined below) are submitted from GP offices and outpatient clinics to the DDDA annually or biennially. The DDDA thus can provide baseline and follow-up data for members of the DD2 cohort including data on the T2D diagnosis date first recorded in the healthcare system, tobacco smoking, completion of examinations for diabetic foot and eye disease, body mass index (BMI), physician-reported antidiabetic treatment, antihypertensive treatment, hypolipidaemic treatment and routine laboratory measurements such as HbA1c, plasma lipids and albuminuria.

### Administrative and health registries {#s2b3}

Migration and civil status can be ascertained from the CRS[@R4] ([figure 3](#F3){ref-type="fig"}). The Danish National Patient Registry (DNPR)[@R8] maintains complete data on all hospital admissions since 1977 and on all hospital outpatient clinic and emergency room contacts since 1995, including dates of admission and discharge, visit dates, surgical procedures performed and primary and secondary discharge diagnoses coded according to the *International Classification of Diseases*, 8th Revision until the end of 1993 and 10th Revision thereafter. Linkage to the DNPR makes it possible to obtain individual-level information at baseline and during follow-up on diseases and treatments relevant to diabetes, such as cardiovascular events, microvascular complications and dialysis. On the basis of diagnoses in the DNPR, the baseline comorbidity burden of each DD2 participant is calculated using Charlson Comorbidity Index (CCI) scores[@R9] (low: 0 points, medium: 1--2 points, high ≥3 points; diabetes is excluded as it constitutes the index disease). Linkage to the Danish National Health Service Prescription Database (DNHSP)[@R10] provides individual-level information on reimbursable drugs dispensed at all pharmacies in Denmark allowing to track treatment history of each DD2 participant. Pharmacy data include the date of dispensing, as well as amount and type of drug prescribed according to the Anatomical Therapeutic Chemical classification system. The Danish Cancer Registry (DCR)[@R11] has recorded data on cancer diagnoses in Denmark since 1943 and is a valuable resource for studying cancer in patients with T2D. Linkage to the Danish Register of Causes of Death (DRCD)[@R12] allows evaluation of cause-specific mortality, while linkage to the Statistics Denmark database provides socioeconomic data, for example, on education, job level and income. The National Health Insurance Service Registry contains information on all services provided by GPs and specialists in Denmark since 1990, including physiotherapists, dentists and chiropractors. Data on services include the number of contacts, health service provider and type of service (eg, consultation, blood glucose measurement or vaccination).[@R13]

![Schematic overview of individual-level data linkage in the DD2 cohort using the civil registration number as personal identification. DD2, Danish Centre for Strategic Research in Type 2 Diabetes.](bmjopen-2017-017273f03){#F3}

### Questionnaire data 2016 {#s2b4}

By June 2016, all enrolled DD2 patients were sent questionnaires to gather follow-up data (described below) as well as data on the prevalence of diabetic neuropathy. Neuropathy-related questions included, among others, the Michigan Neuropathy Screening Instrument questionnaire, the Douleur Neuropathique 4 questionnaire and other pain-related questions. A random sample of patients reporting symptoms of painful and non-painful neuropathy as well as a random sample of control patients without symptoms will be invited for an in-depth neuropathy examination during 2016--2018, which will allow comprehensive investigation of this late diabetic complication. The questionnaires also maintained follow-up questions regarding the lifestyle factors included in the baseline study interview, including alcohol use, smoking habits and physical activity ([figure 2](#F2){ref-type="fig"}). Preliminary data from this questionnaire survey have revealed a remarkable response rate of 85%.

Also, quality of life 12-Item Short Form Health Survey (SF-12) questionnaires have recently been emailed to all DD2 cohort members with a known email address (n=2629). As of August 2016, 1002 patients (38% of those with email addresses) had responded to this questionnaire. Follow-up SF-12 questionnaires will be emailed automatically every second year.

Baseline characteristics of study participants {#s2c}
----------------------------------------------

An overview of the interview and clinical examination data collected from the 7011 patients enrolled in the DD2 between November 2010 and February 2016 is provided in [table 2](#T2){ref-type="table"}.

###### 

Characteristics of patients with newly diagnosed type 2 diabetes enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project during November 2010--February 2016

  -------------------------------------------------------------------------------------------------------------------
  Variables                                                                           Patients with type 2 diabetes
  ----------------------------------------------------------------------------------- -------------------------------
  **Persons enrolled in DD2 by February, 2016, n (%)**                                7011 (100)

    Enrolled from general practitioners' offices, n (%)                               3688 (53)

    Enrolled from hospital clinics, n (%)                                             3323 (47)

  Median age (IQR), years                                                             61 (52--68)

  Minimum--maximum age, years                                                         17--95

  Gender, n (%)                                                                       

    Male                                                                              4065 (58)

    Female                                                                            2946 (42)

  Resting heart rate, median (IQR)                                                    70 (63--79)

  Waist circumference, median\                                                        106 (97--116)
  (IQR), cm                                                                           

  Waist--hip ratio in men, median (IQR)                                               1.02 (0.97--1.06)

  Waist--hip ratio in women, median (IQR)                                             0.92 (0.87--0.97)

  Median weight at 20 years of age (IQR), kg                                          70 (60--80)

    Weight unknown at age 20, n (%)                                                   929 (13)

  Median maximum lifetime weight (IQR), kg                                            100 (86--115)

    Maximum lifetime weight unknown, n (%)                                            75 (1)

  Alcohol use, n (%)                                                                  

    Maximum 14/21 drinks/week (women/men)                                             6539 (93)

    More than 14/21 drinks/week (women/men)                                           472 (7)

  Days per week with 30+ min of physical activity (days)                              

    0                                                                                 1161 (17)

    1                                                                                 488 (7)

    2                                                                                 891 (13)

    3                                                                                 954 (14)

    4                                                                                 622 (9)

    5                                                                                 681 (10)

    6                                                                                 317 (5)

    7                                                                                 1897 (27)

  Regular sports activities, n (%)                                                    

    Yes                                                                               2748 (39)

    No                                                                                4262 (61)

  Level of physical activity during the past year, n (%)                              

    Hard physical training and competitive sports several times a week                55 (1)

    Leisure sports, heavy garden work or similar activity at least 4 hours per week   1370 (20)

    Walking, cycling or other light exercise at least 4 hours per week                4298 (61)

    Reading, television watching or other sedentary activity                          1288 (18)

  Family history of diabetes, n (%)                                                   

    Yes                                                                               3717 (53)

    No                                                                                2696 (39)

    Don't know                                                                        598 (9)

  Median fasting blood glucose (IQR), mmol/L\*                                        7.1 (6.4--8.3)

  Median C-peptide†‡ (IQR), pmol/L                                                    1161 (865--1570)

  Glutamic acid decarboxylase antibodies§                                             

   ≤30 kU/L, N (%)                                                                    5655 (97)

   \>30 kU/L, N (%)                                                                   161 (3)

  Median alanine-aminotransferases¶ (IQR), U/L                                        27 (20--38)

  Median pancreatic amylase¶ (IQR), U/L                                               23 (16--30)

  Median C reactive protein¶ (IQR), mg/L                                              2.1 (1.0--4.8)
  -------------------------------------------------------------------------------------------------------------------

\*Currently analysed for the first consecutive 5363 DD2 patients.

†Reference range: 400--1600 pmol/L.

‡Currently analysed for the first consecutive 5800 DD2 patients.

§Currently analysed for the first consecutive 5816 DD2 patients.

¶Currently analysed for the first consecutive 1018 DD2 patients.

As of February 2016, the DD2 cohort consisted of 4065 (58%) men, the median age was 61 years (IQR: 52--68 years) and 3717 (53%) patients had a known family history of diabetes. In regard to exercise, 1161 patients (17%) reported less than 30 min and 1897 patients (27%) reported at least 30 min of physical activity 7 days per week. Overall, 2748 patients (39%) reported regular sports activities. At baseline, 7% (n=472) consumed more alcohol per week than the recommended maximum safe amount in Denmark (maximum of 14/21 drinks per week for women/men). Weight at 20 years of age was available for 6082 study participants, with a median value of 70 kg (IQR: 60--80 kg). The median value of maximum lifetime weight was 100 kg (IQR: 86--115 kg) in the cohort. Median waist--hip ratios were 1.02 (IQR: 0.97--1.06) in men and 0.92 (IQR: 0.87--0.97) in women. To date, biological samples have been obtained from more than 93% of cohort members, with a median fasting blood glucose measurement of 7.1 mmol/L (minimum--maximum: 2.5--29 mmol/L) and a median C-peptide measurement of 1161 pmol/L (IQR: 865--1570 pmol/L).[@R14]

By September 2015, 5115 patients (73%) had been linked to the DDDA quality-of-care database ([table 3](#T3){ref-type="table"}).

###### 

Characteristics of 5115 patients enrolled in the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project, which currently can be linked to the Danish Diabetes Database for Adults

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                                                                             Patients with type 2 diabetes
  --------------------------------------------------------------------------------------------------------------------- -------------------------------
  **N (%) of DD2 participants who could be linked to the Danish Diabetes Database for Adults, as of September 2015.**   5115 (73)

  Tobacco smoking, n (%)                                                                                                

    Never smoker                                                                                                        2254 (44)

    Former smoker                                                                                                       1649 (32)

    Current smoker, daily                                                                                               886 (17)

    Current smoker, occasionally                                                                                        55 (1)

    Smoking status listed as unknown                                                                                    271 (5)

  **Men (n=2984)**                                                                                                      

  Median height (IQR), cm                                                                                               178 (174--183)

    Height missing, n (%)                                                                                               709 (24)

  Current median weight (IQR), kg                                                                                       96 (85--110)

    Weight missing, n (%)                                                                                               229 (8)

  Current BMI, n (% of those with known BMI)                                                                            

   \<18.5                                                                                                               2 (0)

    18.5--24.9                                                                                                          250 (11)

    25--29.9                                                                                                            833 (37)

    30+                                                                                                                 1183 (52)

    BMI missing                                                                                                         716

  **Women (n=2131)**                                                                                                    

  Median height (IQR), cm                                                                                               164 (160--169)

    Height missing, n (%)                                                                                               561 (26)

  Current median weight (IQR), kg                                                                                       84 (71--96)

    Weight missing, n (%)                                                                                               188 (4)

  Current BMI, n (% of those with\                                                                                      
  known BMI)                                                                                                            

   \<18.5                                                                                                               8 (1)

    18.5--24.9                                                                                                          240 (15)

    25--29.9                                                                                                            458 (29)

    30+                                                                                                                 861 (55)

    BMI missing                                                                                                         564

  HbA1c value                                                                                                           

   \<7%                                                                                                                 3592 (70)

    7.0%--8.0%                                                                                                          824 (16)

    8.0%--9.0%                                                                                                          303 (6)

   ≥9.0%                                                                                                                313 (6)

    HbA1c missing                                                                                                       83 (2)

  Albuminuria, N (%)                                                                                                    

    Albumin--creatinine ratio \<30 mg/g                                                                                 3565 (70)

    Albumin--creatinine ratio 30--300 mg/g                                                                              830 (16)

    Albumin--creatinine ratio ≥300 mg/g                                                                                 110 (2)

    Albuminuria--creatinine ratio missing                                                                               610 (12)

  Blood pressure, median (IQR), mm Hg                                                                                   

    Systolic                                                                                                            130 (124--140)

    Diastolic                                                                                                           80 (74--85)

  Lipids, median (IQR), mmol/L                                                                                          

    Total cholesterol                                                                                                   4.4 (3.7--5.1)

    HDL cholesterol                                                                                                     1.2 (1.0--1.5)

    LDL cholesterol                                                                                                     2.2 (1.7--2.8)

    Triglycerides                                                                                                       1.6 (1.2--2.4)

  Physician-reported antidiabetic treatment, n (%)\*                                                                    

    Insulin only                                                                                                        59 (1)

    Insulin and oral antidiabetic treatment                                                                             306 (6)

    Oral antidiabetic treatment                                                                                         3993 (78)

    None                                                                                                                757 (15)

  Physician-reported antihypertensive treatment, n (%)                                                                  3523 (69)

  Physician-reported ACE inhibitor or ATII-antagonist treatment, n (%)                                                  2786 (54)

  Physician-reported hypolipidaemic treatment                                                                           3373 (66)

  Eye screening completed                                                                                               2762 (54)

  Foot examination completed                                                                                            4362 (85)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

\*Within the year prior to enrolment in the DD2 cohort.

ATII-antagonist, angiotensin 2 antagonist; BMI, body mass index; HbA1c, glycosylated haemoglobin A; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Of the 3835 patients with a known BMI value, 37% of men were overweight at DD2 enrolment and 52% were obese, while 29% of women were overweight and 55% were obese. Seventeen per cent (n=886) were current daily smokers, and 32% (n=1649) were former smokers. Most had an HbA1c value below 7.0% (70%) and 4358 (85%) had received antidiabetic treatment within the year prior to enrolment; 59 patients (1%) were taking only insulin and 3993 (78%) received only oral antidiabetic treatment, as confirmed by routine prescription data from DNHSP. A diabetic eye examination had been performed on 2762 (54%) cohort members and a foot examination on 4362 (85%). At DD2 enrolment, microalbuminuria was present in 16% of patients, and macroalbuminuria was present in 2%. Median systolic/diastolic blood pressure was 130/80, and 3523 patients (69%) were being treated for hypertension. Median total cholesterol was 4.4 (IQR: 3.7--5.1) mmol/L; 3373 patients (66%) were receiving hypolipidaemic treatment. Linkage of the DD2 cohort to the DNPR and DNHSP revealed that approximately one-third of patients had hospital-diagnosed comorbidity (CCI score ≥1 point) prior to enrolment. Twenty-two per cent had hospital-diagnosed macrovascular disease, and 15% had microvascular complications prior to enrolment ([table 4](#T4){ref-type="table"}).

###### 

Comorbidities (determined through linkage with the DNPR) and use of medications (determined through linkage with the DNHSP) at enrolment among the first 7011\* patients with newly diagnosed type 2 diabetes enrolled in the DD2 project

  Variables                                                                       Patients with type 2 diabetes
  ------------------------------------------------------------------------------- -------------------------------
  **Persons enrolled in DD2 by February 2016, n (%)**                             7011 (100)
  Charlson Comorbidity Index score†                                               
    0                                                                             4807 (69)
    1--2                                                                          1820 (26)
    3+                                                                            384 (5)
  Charlson Comorbidity Index conditions at baseline, n (%)                        
    Myocardial infarction                                                         345 (5)
    Congestive heart failure                                                      283 (4)
    Peripheral vascular disease                                                   309 (4)
    Cerebrovascular disease                                                       465 (7)
    Dementia                                                                      13 (0.2)
    Chronic pulmonary disease                                                     510 (7)
    Connective tissue disease                                                     183 (3)
    Ulcer disease                                                                 126 (2)
    Mild liver disease                                                            111 (2)
    Hemiplegia                                                                    19 (0.3)
    Moderate to severe renal disease                                              117 (2)
    Any tumour                                                                    508 (7)
    Leukaemia                                                                     15 (0.2)
    Lymphoma                                                                      26 (0.4)
    Moderate to severe liver disease                                              16 (0.2)
    Metastatic solid tumour                                                       43 (0.6)
    HIV/AIDS                                                                      9 (0.1)
  Any macrovascular complications                                                 1511 (22)
  Any microvascular complications                                                 1035 (15)
    Diabetic neuropathy                                                           230 (3)
    Diabetic retinopathy                                                          682 (10)
    Diabetic nephropathy                                                          209 (3)
  Mental disorder (based on discharge and treatment codes for mental illness)\*   1456 (21)
  Antidiabetic treatment, n (%)\*‡                                                
    Insulin only                                                                  80 (1)
    Insulin and oral antidiabetic treatment                                       396 (6)
    Oral antidiabetic treatment                                                   5387 (78)
    None                                                                          1053 (15)
  Glucose-lowering drugs, n (%)\*‡                                                
    Biguanides (metformin)                                                        5631 (81)
    Insulin                                                                       476 (7)
    Sulfonylureas                                                                 463 (7)
    DPP-4 inhibitors                                                              653 (9)
    GLP-1 analogues                                                               378 (5)
    SGLT-2 inhibitors                                                             57 (0.8)
    Meglitinides                                                                  7 (0.1)
    Thiazolidinediones (glitazones)                                               1 (0.01)
    Alpha-glucosidase inhibitors                                                  4 (0.06)
  Antihypertensive treatment excluding loopdiuretics, n (%)\*‡                    4991 (72)
  ACE inhibitors or ATII-antagonist treatment, n (%)\*‡                           4157 (60)
  Hypolipidaemic treatment, n (%)\*‡                                              4886 (71)
  Oral steroids, n (%)\*‡                                                         430 (6)

\*At the time of analysis, full prescription data were available only until 31 December 2015. Therefore, variables based on data from the DNHSP are for a subcohort numbering 6916 patients.

†Diabetes mellitus not included in the score as it constitutes the index disease. Comorbidity categories include DNPR derived data on cancer; more detailed cancer data are available from the Danish Cancer Registry.

‡Within the last year prior to DD2 enrolment.

ATII-antagonist, angiotensin 2 antagonist; DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DNPR, Danish National Patient Registry; DNHSP, Danish National Health Service Prescription; DPP-4-inhibitors, dipeptidylpeptidase 4 inhibitors; GLP-1 analogues, glucagon-like peptide 1 analogues; SGLT-2 inhibitors, sodium glucose cotransporter 2 inhibitors.

Findings to date {#s3}
================

Mortality ratios {#s3a}
----------------

The DD2 cohort has been followed for a total of 18 862 person-years (PY) and a mean of 2.7 years. A total of 212 patients have died, yielding an all-cause mortality rate (MR) of 1.12 per 100 PY (95% CI 0.97 to 1.29), with differences by gender (MR for women: 0.81 (95% CI 0.62 to 1.03); MR for men: 1.36 (95% CI 1.15 to 1.60)). As expected, all-cause MR increased with age ([table 5](#T5){ref-type="table"}).

###### 

Number of deaths and overall, age-specific and gender-specific mortality rates (per 100 person-years) for the baseline cohort of 7011 DD2 patients

  Variables          Number of deaths   MR (95% CI)
  ------------------ ------------------ ---------------------
  Total DD2 cohort   212                1.12 (0.97 to 1.29)
  Gender                                
    Women            65                 0.81 (0.62 to 1.03)
    Men              147                1.36 (1.15 to 1.60)
  Age (years)                           
   \<40              2                  0.23 (0.03 to 0.83)
    40--59           37                 0.50 (0.35 to 0.69)
    60--79           149                1.47 (1.25 to 1.73)
   ≥80               24                 4.97 (3.19 to 7.40)

Median follow-up time from date of enrolment to death or to date of latest data extraction from the Civil Registration System was 2.68 years (IQR: 1.67--3.63 years).

DD2, Danish Centre for Strategic Research in Type 2 Diabetes; MR, mortality rate.

Key findings {#s3b}
------------

Several baseline cross-sectional studies based on preliminary findings for parts of the current DD2 cohort were published in 2014--2016.[@R15] Parental history of T2D was associated with younger age at diagnosis (adjusted prevalence ratio (aPR) for age \<40 years: 1.66 (95% CI 1.19 to 2.31); aPR for age 40--60 years: 1.36 (95% CI 1.24 to 1.48)), as well as poorer glucose control at diagnosis (aPR for fasting blood glucose \<6.5 mmol/L: 0.80 (95% CI 0.62 to 1.02) and aPR for fasting blood glucose ≥7.5 mmol/L: 1.47 (95% CI 1.20 to 1.80)). No associations were observed for anthropometric and lifestyle factors, while parental history tended to be negatively associated with the high beta cell function phenotype[@R18] (aPR 0.79 (95% CI 0.61 to 1.01)). This suggests that patients with T2D may not inherit diabetes primarily as a result of family-learned lifestyle habits (physical inactivity and overeating), but rather as a result of a constitutional impairment of insulin action/secretion.[@R18] In studies of DD2 biobank data, a 16% prevalence of elevated ALAT (\>38 IU/L for women and \>50 IU/L for men)[@R15] and a 40% prevalence of elevated CRP (\>3.0 mg/L)[@R16] have been found among newly diagnosed patients with T2D. As well, potentially modifiable predictors of elevated ALAT/CRP have been identified, including low physical activity (ALAT: relative risk (RR) 1.4, 95% CI 1.04 to 1.93; CRP: RR 1.46, 95% CI 1.11 to 1.91).[@R15] Such biomarkers may have an impact on the clinical outcome of diabetes, which future prospective studies using DD2 data will be able to examine.

In another study, patients with incident T2D were followed during their first year postdiagnosis. It was found that 74% were receiving glucose-lowering therapy, with 88% receiving monotherapy, mainly metformin. Factors associated with receiving any glucose-lowering therapy included young age (RR 1.29, 95% CI 1.16 to 1.44), central obesity (RR=1.23, 95% CI 1.04 to 1.44), large weight gain since youth (RR=1.10, 95% CI 1.03 to 1.18), lack of regular physical activity (RR=1.07, 95% CI 1.01 to 1.15), high baseline fasting blood glucose (RR=1.25, 95% CI 1.10 to 1.42) and high comorbidity burden (RR=1.20, 95% CI 1.05 to 1.38).[@R17]

A publication list is provided at [www.dd2.nu](www.dd2.nu). The results of many ongoing long-term prospective studies will be reported in years to come including genotype studies investigating the association between genotypes and pharmacological treatment strategies on relevant endpoints like glycaemic control and albuminuria.

Strengths and limitations {#s4}
=========================

The DD2 project has established a large population-based cohort of newly diagnosed patients with T2D, with demographic, anthropometric, lifestyle and clinical data. Furthermore, the project maintains a valuable biobank. Use of the unique individual-level CPR identifier makes it possible to avoid multiple registrations and to take advantage of existing data in Danish health and administrative registries in a cost-effective way. These registries also provide a source of long-term follow-up data. Since much of the data are recorded by health personnel during diagnosis and treatment, and not for research purposes, investigator bias is reduced. In addition, the validity of Danish registry data is high. As an example, reporting of cancer to the DCR is mandatory, and completeness is secured by cross-checking with other registries including DRCD and the Danish Pathology Registry.[@R11] In the DNPR, the positive predictive value of, for example, hospital discharge diagnoses included in the CCI is 94%--100%.[@R22]

A few limitations of the DD2 cohort must be noted. First, while DD2 and DDDA data are nearly complete for demographic variables and for many clinical variables such as smoking, physical activity, hip--waist ratio and resting heart rate, the proportion of missing data is large for some variables. For example, in the DDDA, BMI is missing for 26% of women. However, waist--hip ratio is available for 100% of the DD2 cohort and constitutes a better predictor of cardiovascular complications than BMI.[@R23] Second, linkage to the DDDA currently is only possible for 73% of DD2 participants, partly explained by the data delay associated with the DDDA's role as a clinical quality improvement registry. Its mandate is to report on quality of care based on data collected during the previous year (ie, patients need to have prevalent T2D for 1--2 years before they are eligible for quality-of-care assessment). In contrast, the DD2 project focuses on incident T2D and is tasked with collecting data at time of diagnosis.[@R7] Moreover, while reporting to the DDDA by GPs became mandatory in 2013, all GP reporting discontinued in September 2014 due to conflicting interpretation of legal issues concerning automated data transmission. Third, while it was planned for the DD2 cohort to recruit newly diagnosed T2D patients, approximately 85% already have initiated glucose-lowering treatment at enrolment. This hampers analyses of biomarkers among treatment-naive patients with T2D. However, the exact start date of glucose-lowering therapy can be ascertained from prescription registries. Fourth, since predominantly patients from outpatient specialist clinics were enrolled in early study years, that is, during 2010--2012, the cohort initially may have contained newly diagnosed patients with T2D with more advanced disease than average. However, the baseline data presented in this paper are similar to baseline data in a recent registry-based cohort study investigating patients with T2D from the Northern Region of Denmark at initiation of their first glucose-lowering therapy,[@R24] thus reassuring that exposures of interest are represented for Danish patients withT2D in earlier phases of the disease. Finally, a large proportion of patients in the DD2 cohort were enrolled during the last few years, which limits current opportunities for conducting long-term follow-up studies.

In the future, the DD2 cohort will serve as a strong national and international resource for recruiting patients to nested case studies and clinical trials, postmarketing surveillance, large-scale genome studies, intervention studies, for example, in patients with rare diabetic subtypes, and follow-up studies of diabetes complications.

Collaboration {#s5}
=============

More information about the DD2 cohort can be found at the DD2 website [www.dd2.nu](www.dd2.nu). The DD2 project has a Steering Group with members from GP practices/hospital research units in all regions of Denmark. The Steering Group strongly encourages national and international collaboration. Interested researchers can contact Director Dr Henning Beck-Nielsen at henning.beck-nielsen\@syd.dk.
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